Neuroendocrinology of prolonged critical illness: Effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues

被引:158
作者
Van den Berghe, G [1 ]
De Zegher, F
Baxter, RC
Veldhuis, JD
Wouters, P
Schetz, M
Verwaest, C
Van der Vorst, E
Lauwers, P
Bouillon, R
Bowers, CY
机构
[1] Univ Louvain, Univ Hosp Gasthuisberg, Dept Intens Care Med, B-3000 Louvain, Belgium
[2] Univ Louvain, Univ Hosp Gasthuisberg, Dept Pediat, B-3000 Louvain, Belgium
[3] Univ Louvain, Univ Hosp Gasthuisberg, Dept Endocrinol, B-3000 Louvain, Belgium
[4] Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia
[5] Univ Virginia, Hlth Sci Ctr, Dept Med, Div Endocrinol, Charlottesville, VA 22908 USA
[6] Tulane Univ, Med Ctr, Dept Med, Div Endocrinol, New Orleans, LA 70112 USA
关键词
D O I
10.1210/jc.83.2.309
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The catabolic state of prolonged critical illness is associated with a low activity of the thyrotropic and the somatotropic axes. The neuroendocrine component in the pathogenesis of these low activity states was assessed by investigating the effects of continuous intra venous infusions of TRH, GH-releasing peptide-2 (GHRP-2), and GHRH. Twenty adult patients, critically ill for several weeks, were studied during two consecutive nights. They had been randomly allocated to one of three combinations of peptide infusions, each administered in random order: TRH (one night) and placebo (other night), TRH + GHRP-2 (one night) and GHRP-2 (other night), or TRH + GHRH + GHRP-2 (one night) and GHRH + GHRP-2 (other night). The peptide infusions were started after a 1-mu g/kg bolus and infused (1 mu g/kg per h) until 0600 h. Blood sampling was performed every 20 min, and pituitary hormone secretion was quantified by deconvolution analysis. Reduced pulsatile fraction of TSH, GH, and PRL secretion and low serum concentrations of T-4, T-3, insulin growth factor-I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were documented in the untreated state. Infusion of TRH alone or in combination with GH secretagogues augmented nonpulsatile TSH release 2-to 5-fold; only TRH + GHRP-2 increased pulsatile TSH secretion (4-fold). Average rises in T-4 (40-54%) and in T-3 (52-116%) were obtained with all three combinations, whereas reverse T-3 levels did not increase, except when TRH was infused alone. Pulsatile GH secretion was amplified >6- and >10-fold, respectively, by GHRP-2 and GHRH + GHRP-2 infusions, generating mean increases of serum IGF-I (66% and 106%), IGFBP-3 (50% and 56%), and ALS (65% and 97%) within 45 h. The addition of TRH did not alter the GH secretory patterns. TRH infusion increased PRL release only when combined with GH secretagogues. No effects on serum cortisol were detected. In conclusion, the pathogenesis of the low activity state of the thyrotropic and somatotropic axes in prolonged critical illness appears to have a neuroendocrine component, because these axes are both readily activated by coinfusion of TRH and GH secretagogues.
引用
收藏
页码:309 / 319
页数:11
相关论文
共 52 条
[1]   REDUCED TISSUE THYROID-HORMONE LEVELS IN FATAL ILLNESS [J].
AREM, R ;
WIENER, GJ ;
KAPLAN, SG ;
KIM, HS ;
REICHLIN, S ;
KAPLAN, MM .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (09) :1102-1108
[2]   THE RELATIONSHIP BETWEEN SERUM TRIIODOTHYRONINE AND THYROTROPIN DURING SYSTEMIC ILLNESS [J].
BACCI, V ;
SCHUSSLER, GC ;
KAPLAN, TB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1982, 54 (06) :1229-1235
[3]  
Baxter RC, 1997, ENDOCRINOL METAB, V4, P65
[4]   INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEINS IN THE HUMAN CIRCULATION - A REVIEW [J].
BAXTER, RC .
HORMONE RESEARCH, 1994, 42 (4-5) :140-144
[5]   CIRCULATING LEVELS AND MOLECULAR-DISTRIBUTION OF THE ACID-LABILE (ALPHA) SUBUNIT OF THE HIGH-MOLECULAR-WEIGHT INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN COMPLEX [J].
BAXTER, RC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (05) :1347-1353
[6]   RADIOIMMUNOASSAY OF GROWTH-HORMONE DEPENDENT INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEIN IN HUMAN-PLASMA [J].
BAXTER, RC ;
MARTIN, JL .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (06) :1504-1512
[7]   VARIABLE BIOLOGICAL-ACTIVITY OF THYROID-STIMULATING HORMONE [J].
BECKPECCOZ, P ;
PERSANI, L .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1994, 131 (04) :331-340
[8]   ACQUIRED GROWTH-HORMONE RESISTANCE IN PATIENTS WITH HYPERCATABOLISM [J].
BENTHAM, J ;
RODRIGUEZARNAO, J ;
ROSS, RJM .
HORMONE RESEARCH, 1993, 40 (1-3) :87-91
[9]  
BOUILLON R, 1974, ANN ENDOCRINOL-PARIS, V35, P606
[10]   ON THE INVITRO AND INVIVO ACTIVITY OF A NEW SYNTHETIC HEXAPEPTIDE THAT ACTS ON THE PITUITARY TO SPECIFICALLY RELEASE GROWTH-HORMONE [J].
BOWERS, CY ;
MOMANY, FA ;
REYNOLDS, GA ;
HONG, A .
ENDOCRINOLOGY, 1984, 114 (05) :1537-1545